ORKA vs. INDV, APGE, IRON, BHC, BEAM, ARQT, BHVN, SDGR, EWTX, and JANX
Should you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Indivior (INDV), Apogee Therapeutics (APGE), Disc Medicine (IRON), Bausch Health Companies (BHC), Beam Therapeutics (BEAM), Arcutis Biotherapeutics (ARQT), Biohaven (BHVN), Schrödinger (SDGR), Edgewise Therapeutics (EWTX), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry.
Oruka Therapeutics vs. Its Competitors
Oruka Therapeutics (NASDAQ:ORKA) and Indivior (NASDAQ:INDV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, community ranking, risk, analyst recommendations, valuation, earnings and institutional ownership.
Indivior has higher revenue and earnings than Oruka Therapeutics. Indivior is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Indivior had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 7 mentions for Indivior and 2 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.78 beat Indivior's score of 1.35 indicating that Oruka Therapeutics is being referred to more favorably in the media.
Oruka Therapeutics has a net margin of 0.00% compared to Indivior's net margin of -3.96%. Oruka Therapeutics' return on equity of -24.96% beat Indivior's return on equity.
Oruka Therapeutics presently has a consensus target price of $40.38, suggesting a potential upside of 220.44%. Indivior has a consensus target price of $15.00, suggesting a potential upside of 9.81%. Given Oruka Therapeutics' higher probable upside, equities analysts plainly believe Oruka Therapeutics is more favorable than Indivior.
Oruka Therapeutics received 9 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 95.24% of users gave Oruka Therapeutics an outperform vote.
56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 24.7% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Oruka Therapeutics has a beta of -0.38, suggesting that its share price is 138% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.
Summary
Oruka Therapeutics and Indivior tied by winning 9 of the 18 factors compared between the two stocks.
Get Oruka Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oruka Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ORKA) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy ORKA Stock Free ORKA Stock Alerts